The government on Wednesday approved a foreign investment of up to Rs 9,589 crore in Suven Pharmaceuticals by Cyprus-based Berhyanda Ltd.
The approval is for acquisition of up to 76.1 per cent shares of Suven Pharmaceuticals by Berhyanda by way of transfer of shares from existing promoter shareholders and public shareholders through mandatory open offer, an official release said after the meeting of Cabinet Committee on Economic Affairs.
The aggregate foreign investment may increase to up to 90.1 per cent in Suven, the release said.
The proposal has been evaluated by Sebi, RBI, CCI and other relevant agencies.
The release further said the approval has been granted after examination of the proposal by departments concerned, RBI and Sebi and is subject to the fulfilment of all rules and regulations as applicable in this regard.
Total foreign direct investment (FDI) in the pharmaceutical sector has been Rs 43,713 crore during last five years (from 2018-19 to 2022-23). The sector has witnessed significant growth in FDI of 58 per cent in the last financial year.
Also Read
FDI inflows decline 16% to $71 billion for first time in a decade: RBI data
FDI inflows into India rise 10%, outflows shrink 16% in 2022: Unctad
Cyprus, Israel, Greece join forces on energy, defence, economy and tourism
Will Saudi-Iran accord have a domino effect and stabilize the Middle East?
Rajasthan cabinet approves creation of 19 new districts, three divisions
Share of AI/ML in telecom firms' workforce rises to 20% on 5G rollout
Gas prices likely pushed up inflation in Aug, other costs probably slowed
India economy added 52 million new formal jobs in FY20-23: Report
Govt seeks to allay concern over 'retaliatory' duty cut on US apples
India's August retail inflation eases to 6.83%, but still above RBI band
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)